Ulcerative colitis (UC) can lead to progressive intestinal damage and massive restrictions in the daily lives of those affected [2]. With the approval of SKYRIZI® (risankizumab), a new first-line therapy is now available to UC patients [1]. Data from pivotal phase 3 clinical trials show rapid and sustained efficacy and make long-term goals such as mucosal healing achievable in up to 76% of patients without prior biologic failure$ possible [3, 4].
You May Also Like
- Pustular psoriasis
What is known about inflammatory mechanisms in PPP and GPP?
- Diabetes-related cardiovascular diseases
Ferroptosis: key mechanisms and novel therapeutic approaches
- Atrial fibrillation
What’s new with the “pace-and-ablate” strategy?
- De-escalation strategies
De-escalation strategies – less is more
- Pathogens in the brain
When infections trigger strokes
- Diabetes mellitus
Treatment of comorbidities in older people
- Pulmonary hypertension
PH and lung diseases
- Advanced NSCLC